D&D Pharmatech, a new drug development company, announced Monday that its Phase 2 study of 'DD01,' a treatment for metabolic dysfunction-associated steatohepatitis (MASH), has been selected as a Late-Breaking Abstract (LBA) for the 'EASL Congress 2026,' the annual meeting of the European Association for the Study of the Liver (EASL), to be held in Spain in May.
DD01, developed in-house by D&D Pharmatech, is a dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors. The company has completed a 48-week Phase 2 clinical trial in the United States and is currently analyzing the data. Top-line data, including biopsy results, is expected to be received after mid-May.
Founded in 1966, EASL is Europe's largest research society for liver diseases. This year's annual meeting will be held in Barcelona, Spain, from May 27 to 30. More than 10,000 medical professionals and researchers from around the world are expected to attend to share the latest research, clinical data, and treatments related to liver diseases. The LBA is a session that exceptionally grants presentation opportunities to the latest research findings with high academic value and innovation, even after the regular abstract submission deadline, and is considered a notable track within the conference.
D&D Pharmatech plans to include 48-week biopsy data results in the LBA presentation materials. The company has completed dosing and safety follow-up for all patients and is currently conducting follow-up statistical analysis.
The lead author of the study is Professor Mazen Noureddin, a world-renowned authority in MASH and liver disease and the principal investigator of the DD01 Phase 2 trial. Following the presentation of 12-week results at the American Association for the Study of Liver Diseases (AASLD) in November 2025, Professor Noureddin is leading the presentation of 48-week data at this EASL meeting, driving the clinical development and academic validation of DD01.
"As data on liver fibrosis and histological improvements confirmed through biopsy after 48 weeks of dosing will be disclosed for the first time, we will focus our capabilities on generating tangible results such as global partnerships starting from this presentation," D&D Pharmatech CEO Lee Seul-ki said.
